Trelagliptin is used for the treatment of type 2 diabetes. It has been approved for use as a first line treatment when metformin cannot be used. Trelagliptin was developed by Syrrx Inc..
The API has now reached off-patent status, after being launched in 2015.

The information provided above is sourced from Chemrobotics PharmaVetPat https://chemroboticspharma.com/pharmVetPat
to find out more, including patent landscape and routes of synthesis, please contact our sales team.

According to PharmaTrade, Trelagliptin was exported from India in 2023, with an average price over the period of $2508 /kg.
The key suppliers were Metrochem API, with a focus on markets in MEA.

For enquiries regarding more detailed trade data of Trelagliptin and many others, contact info@pharmacheminvestor.com